Related coverage linked through entity extraction aliases.
Apr 27, 2026
20/20 BioLabs began trading on Nasdaq under ticker AIDX and disclosed a contingent financing agreement of up to $40 million. It later signed an exclusive U.S. license deal with ROKIT to add CKD prediction to OneTest for Longevity.
Apr 02, 2026
20/20 BioLabs has licensed ROKIT Healthcare's chronic kidney disease prediction algorithm for its longevity platform, expanding from inflammation tracking to specific risk detection. The technology will be integrated into the company's OneTest for Longevity program, with potential applications for improving outcomes in regenerative treatments. The agreement includes revenue sharing and could lead to exclusive commercialization rights for ROKIT in East Asian markets.
Mar 19, 2026
Bayer's Phase III FIND-CKD trial shows finerenone significantly slows kidney function decline in non-diabetic chronic kidney disease patients. The drug met its primary endpoint with improved eGFR slope over 32 months, marking its fifth consecutive positive Phase III trial. Bayer plans to submit the data to the FDA for label expansion into non-diabetic CKD.
Mar 14, 2026
New research demonstrates RNA therapies can enhance heart regeneration after injury, while RNA biomarkers improve prediction of cardiovascular complications in chronic kidney disease patients.
Mar 13, 2026
China's NMPA approved Desidustat Tablets on March 13, 2026, for treating anemia in non-dialysis CKD patients. Clinical trials showed the oral HIF-PHI was non-inferior to erythropoietin in maintaining hemoglobin levels with improved quality of life.
Mar 09, 2026
New research demonstrates machine learning can optimize drug dosing, identifies biomarkers of treatment response, and validates prognostic criteria for long-term kidney survival in pediatric lupus nephritis patients.
Mar 05, 2026
Finerenone met its primary endpoint in reducing albuminuria in type 1 diabetic kidney disease, marking the first successful drug trial in 30 years for this population. Separately, SGLT2 inhibitors showed superior kidney protection compared to GLP-1 medications in type 2 diabetes patients.
Mar 04, 2026
A systematic review and meta-analysis demonstrates that semaglutide significantly reduces major adverse cardiovascular events in adults with type 2 diabetes, with particular benefits for nonfatal myocardial infarction and stroke.
Mar 03, 2026
A systematic review of 64 randomized clinical trials found GLP-1 receptor agonists produce greater weight loss in women than men, while the global market is projected to grow from $51.57 billion in 2026 to $112.62 billion by 2032.
Feb 14, 2026
Disc Medicine received a complete response letter from the FDA for bitopertin as a treatment for erythropoietic protoporphyria. The FDA acknowledged the drug lowers PPIX levels but requires evidence from the ongoing Phase 3 APOLLO study before approval.
Feb 13, 2026
Real-world study finds SGLT2 inhibitors reduce chronic kidney disease and acute kidney injury risk more effectively than GLP-1 receptor agonists in patients with type 2 diabetes, with greatest benefits in those without preexisting kidney disease.
